专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08686043B2 Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof 有权
标题翻译：杂环磺酰胺，其用途和药物组合物
公开(公告)号：US08686043B2
公开(公告)日：2014-04-01
申请号：US13596492
申请日：2012-08-28
申请人： Anton Franz Joseph Fliri , Randall James Gallaschun , Christopher John O'Donnell , Jacob Bradley Schwarz , Barbara Eileen Segelstein
发明人： Anton Franz Joseph Fliri , Randall James Gallaschun , Christopher John O'Donnell , Jacob Bradley Schwarz , Barbara Eileen Segelstein
IPC分类号： A01N41/06 , A61K31/18 , A01N43/06 , A61K31/38
CPC分类号： C07D409/14 , C07C307/02 , C07C311/07 , C07C2601/08 , C07C2601/14 , C07D207/08 , C07D213/65 , C07D295/096 , C07D307/22 , C07D307/42 , C07D333/38 , C07D405/12 , C07D407/12 , C07D409/04 , C07D409/12
摘要： The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
摘要翻译：本发明涉及一类化合物，包括具有式I结构的化合物的药学上可接受的盐：如说明书中所定义的。本发明还涉及包含和使用式I化合物的组合物。

2. 发明申请

US20180349779A1 METHOD AND DESCRIPTORS FOR COMPARING OBJECT-INDUCED INFORMATION FLOWS IN A PLURALITY OF INTERACTION NETWORKS 审中-公开
公开(公告)号：US20180349779A1
公开(公告)日：2018-12-06
申请号：US15778448
申请日：2016-11-25
申请人： Anton Franz Joseph FLIRI
发明人： Anton Franz Joseph FLIRI
IPC分类号： G06N5/04 , H04L12/24 , G06F17/30 , G06N3/12
CPC分类号： H04L41/12 , G06F19/00 , Y04S40/164
摘要： A method of tracking information flows through multiple network systems includes selecting a primary network system from a population of primary and secondary network systems, wherein each of the primary and secondary network systems include network nodes, selecting first selected characteristic features that identify network nodes of the primary network system that provide interaction between the selected primary network system and secondary network systems, identifying at least one secondary network system that is capable of interacting with the network nodes of the primary network system, subdividing the primary network into subnetwork systems based on identifying primary network nodes that provide interaction between the primary network system and secondary network nodes, identifying the subnetwork systems that are capable of interacting with one or more network nodes of the secondary network systems, identifying a subnetwork node count of the primary network nodes in each subnetwork, identifying objects that are capable of interacting with the primary network nodes, and determining a coincidence frequency or a coincidence measurement between features of objects interacting with the primary network nodes and the features of the primary network nodes that indicate information exchanges between the primary and secondary network nodes.

3. 发明授权

US06531468B2 Diazabicyclooctane derivatives and therapeutic uses thereof 失效
标题翻译：二氮杂双环辛烷衍生物及其治疗用途
公开(公告)号：US06531468B2
公开(公告)日：2003-03-11
申请号：US09920587
申请日：2001-08-01
申请人： Anton Franz Joseph Fliri , Randall James Gallaschun
发明人： Anton Franz Joseph Fliri , Randall James Gallaschun
IPC分类号： C07D48708
CPC分类号： C07D471/08 , C07D487/08
摘要： The present invention provides diazabicyclooctane derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein the group represents R1 and R2 are selected independently from H, (C1-C6)alkyl, (C1-C6)fluoroalkyl, halogen (e.g., F. Cl, Br, I), cyano, nitro, O—(C1-C6)alkyl, O—(C1-C6)fluoroalkyl, —NHC(O)R4 and —OR4, where R4 and R5 are selected independently from H, (C1-C6)alkyl, and a 5- to 7-membered aryl or heteroaryl ring, or R1 and R2 together with the atoms to which they are attached, form a carbocyclic 5- or 6-membered ring or a heterocyclic 5- or 6-membered ring; and R3 is selected from the group consisting of H, (C1-C6)alkyl, (CH2)m-aryl or (CH2)m-heteroaryl, wherein m is an integer from 1 to 4, each aryl or heteroaryl group optionally substituted with Cl, Br, CN, CF3, O—(C1-C6)alkyl, (C1-C6)alkyl, sulfonyl(C1-C6)alkyl, —CO(C1-C6)alkyl, —CONH2, —CONH(C1-C6)alkyl, —CON((C1-C6)alkyl)2, or CH(OH)(C1-C6)alkyl. The invention also relates to pharmaceutical compositions of a compound of formula (I), and methods of use thereof in the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to processes for the preparation of compounds of formula (I) and intermediates useful therefor.
摘要翻译：本发明提供式（I）的二氮杂双环辛烷衍生物及其药学上可接受的盐，其中基团代表R 1和R 2独立地选自H，（C 1 -C 6）烷基，（C 1 -C 6）氟代烷基，卤素（例如F. Cl，Br，I），氰基，硝基，O-（C1-C6）烷基，O-（C1-C6）氟烷基，-NHC（O）R4和-OR4，其中R4和R5独立地选自H（ C 1 -C 6）烷基和5至7元芳基或杂芳基环，或R 1和R 2与它们连接的原子一起形成碳环5或6元环或杂环5或6 记忆环并且R 3选自H，（C 1 -C 6）烷基，（CH 2）m芳基或（CH 2）m - 杂芳基，其中m是1至4的整数，每个芳基或杂芳基任选被Cl取代，（C 1 -C 6）烷基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，烷基，-CON（（C 1 -C 6）烷基）2或CH（OH）（C 1 -C 6）烷基。本发明还涉及式（I）化合物的药物组合物及其在治疗中的用途的中枢神经系统的疾病，病症或病症。此外，本发明还涉及式（I）化合物的制备方法和可用于其的中间体。

4. 发明申请

US20140323416A1 5-METHYLDIHYDROMORPHONE COMPOUNDS FOR TREATMENT OF PAIN 审中-公开
标题翻译：用于治疗疼痛的5-甲基二氢吡喃酮化合物
公开(公告)号：US20140323416A1
公开(公告)日：2014-10-30
申请号：US14254711
申请日：2014-04-16
申请人： Anthony MARFAT , Peter CORNELIUS , Robert VOLKMANN , Panayiotis ZAGOURAS , Frederick Raymond NELSON , Anton Franz Joseph FLIRI
发明人： Anthony MARFAT , Peter CORNELIUS , Robert VOLKMANN , Panayiotis ZAGOURAS , Frederick Raymond NELSON , Anton Franz Joseph FLIRI
IPC分类号： C07D489/02 , C07H15/26 , C07F9/6561
CPC分类号： C07D489/02 , C07F9/6561
摘要： The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries.
摘要翻译：本公开的方面涉及新型化合物，其含有适用于给予患者的所述化合物或其药学上可接受的盐的制剂。特别地，涉及通式I和II中所述的5-甲基二氢吗啡酮前药化合物，以及该化合物用于治疗与多种慢性人类疾病相关的疼痛的用途，包括例如神经性疼痛和与癌症，手术或损伤相关的疼痛。

5. 发明授权

US11120346B2 Method and descriptors for comparing object-induced information flows in a plurality of interaction networks 有权
公开(公告)号：US11120346B2
公开(公告)日：2021-09-14
申请号：US15778448
申请日：2016-11-25
申请人： Anton Franz Joseph Fliri
发明人： Anton Franz Joseph Fliri
IPC分类号： G06N5/04 , G06F16/28 , H04L12/24 , G16H70/60 , G16H70/40 , G06N3/12
摘要： A method of tracking information flows through multiple network systems includes selecting a primary network system from a population of primary and secondary network systems, wherein each of the primary and secondary network systems include network nodes, selecting first selected characteristic features that identify network nodes of the primary network system that provide interaction between the selected primary network system and secondary network systems, identifying at least one secondary network system that is capable of interacting with the network nodes of the primary network system, subdividing the primary network into subnetwork systems based on identifying primary network nodes that provide interaction between the primary network system and secondary network nodes, identifying the subnetwork systems that are capable of interacting with one or more network nodes of the secondary network systems, identifying a subnetwork node count of the primary network nodes in each subnetwork, identifying objects that are capable of interacting with the primary network nodes, and determining a coincidence frequency or a coincidence measurement between features of objects interacting with the primary network nodes and the features of the primary network nodes that indicate information exchanges between the primary and secondary network nodes.

6. 发明授权

US06552015B2 Azabicycloalkane derivatives and therapeutic uses thereof 失效
标题翻译：氮杂双环烷烃衍生物及其治疗用途
公开(公告)号：US06552015B2
公开(公告)日：2003-04-22
申请号：US09920500
申请日：2001-08-01
申请人： Anton Franz Joseph Fliri , Todd William Butler , Randall James Gallaschun
发明人： Anton Franz Joseph Fliri , Todd William Butler , Randall James Gallaschun
IPC分类号： C07D48708
CPC分类号： C07D401/06 , C07D471/08 , C07D487/08
摘要： The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.
摘要翻译：本发明涉及式（I）化合物及其药学上可接受的盐，其中R 1，R 2，Y，U，W，k，A，E，V，R 4和R 5如本文所定义，药物组合物及其用于抑制5-羟色胺再摄取，抑制5-HT2A 5-羟色胺受体的结合以及治疗中枢神经系统的疾病，病症或病症的方法。此外，本发明还涉及制备式（I）化合物和可用于其的中间体的方法。

7. 发明授权

US06521630B1 Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof 失效
标题翻译：四氢喹唑啉-2,4-二酮及其治疗用途
公开(公告)号：US06521630B1
公开(公告)日：2003-02-18
申请号：US09650486
申请日：2000-08-29
申请人： Anton Franz Joseph Fliri , Todd William Butler , Randall James Gallaschun , John Anthony Ragan , Brian Patrick Jones
发明人： Anton Franz Joseph Fliri , Todd William Butler , Randall James Gallaschun , John Anthony Ragan , Brian Patrick Jones
IPC分类号： A61K31517
CPC分类号： C07D401/14 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/12
摘要： The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): pharmaceutically acceptable salts thereof, wherein A is (CH2)n where n is equal to 0, 1 or 2; U is CH2, NH, or NR3, R1 and R2 are selected independently from H, (C1-C6)alkyl, Cl, F, CN, nitro, CF3, —NHC(O)R6 and —OR7, or R1 and R2, together with the atoms to which they are attached, form a carbocyclic or heterocyclic five- or six-membered ring, R3 is selected from the group consisting of H, (C1-C6)malkyl, C(═O)—(C1-C6)alkyl, where m=1 or 2; R4 and R5 are selected from H, (C1-C6)alkyl, Cl, F, —CF3, —CN, —NHC(═O)R6, —OR7, a 5-to 7-membered aryl or heteroaryl ring, where m, R6 and R7 are as defined above; and R6 and R7 are selected independently from H, (C1-C6)alkyl or a 5- to 7-membered aryl or heteroaryl ring; V is CH, CR3, or N; W is CH2, C(O), or S(O)2; X is C or N; and Y is CH, CR1,CR2, or N. The invention also relates to pharmaceutical compositions containing the same and to methods of use thereof, including in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of 4-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)-propyl-1,2,3,4-tetrahydroquinazoline-2,4-dione compounds and intermediates useful thereof.
摘要翻译：本发明涉及式（I）的四氢喹唑啉-2,4-二酮衍生物：其药学上可接受的盐，其中A是（CH2）n，其中n等于0,1或2; U是CH 2，NH或NR 3，R 1和R 2独立地选自H，（C 1 -C 6）烷基，Cl，F，CN，硝基，CF 3，-NHC（O）R 6和-OR 7或R 1和R 2，与其连接的原子一起形成碳环或杂环的五元或六元环，R 3选自H，（C 1 -C 6）烷基，C（= O） - （C 1 -C 6））烷基，其中m = 1或2; R4和R5选自H，（C1-C6）烷基，C1，F，-CF3，-CN，-NHC（= O）R6，-OR7，5-7元芳基或杂芳基环，其中m ，R6和R7如上所定义; 并且R 6和R 7独立地选自H，（C 1 -C 6）烷基或5至7元芳基或杂芳基环; V是CH，CR 3或N; W是CH 2，C（O）或S（O）2; X为C或N; 并且Y是CH，CR1，CR2或N.本发明还涉及含有该组合物的药物组合物及其使用方法，包括抑制5-羟色胺再摄取，抑制5-HT2A 5-羟色胺受体的结合和治疗中枢神经系统的疾病，病症或病症。此外，本发明还涉及制备4-（4-苯基-1,2,3,6-四氢吡啶-1-基） - 丙基-1,2,3,4-四氢喹唑啉-2， 4-二酮化合物及其有用的中间体。

8. 发明授权

US06372762B1 Substituted bicyclic derivatives for treating central nervous system disorders 失效
标题翻译：用于治疗中枢神经系统疾病的取代的双环衍生物
公开(公告)号：US06372762B1
公开(公告)日：2002-04-16
申请号：US09300262
申请日：1999-04-27
申请人： Anton Franz Joseph Fliri , Todd William Butler
发明人： Anton Franz Joseph Fliri , Todd William Butler
IPC分类号： A61K31445
CPC分类号： C07D209/48 , C07D209/14 , C07D213/38 , C07D235/08 , C07D235/14 , C07D235/26 , C07D239/42 , C07D295/033 , C07D295/073 , C07D295/096 , C07D295/116 , C07D295/135 , C07D295/155 , C07D307/94 , C07D311/96 , C07D403/12 , C07D405/12
摘要： The present invention relates to compounds of the formula and the pharmaceutically acceptable salts and solvates thereof wherein X1, X2, X3, R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating shizophrenic and shizo-affective disorders, and related disorders which may be treated by administering compounds having dopaminergic activity such as the above compounds of formula 1.
摘要翻译：本发明涉及下式的化合物及其药学上可接受的盐和溶剂化物，其中X1，X2，X3，R1，R2，R3和R4如本文所定义。本发明还涉及含有上述化合物的药物组合物以及治疗嗜酸细胞病和丝状病症的方法以及可通过给予具有多巴胺能活性的化合物（例如上述式1化合物）治疗的相关病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式